Yaara Zwang, Ph.D.
Affiliations: | 2009 | BIR Biological Regulation | Weizmann Institute of Science, Rehovot, Israel |
Area:
General Biology, Cell BiologyGoogle:
"Yaara Zwang"Parents
Sign in to add mentor| Yosef Yarden | grad student | 2009 | Weizmann Institute | |
| (Cell fate decisions mediated by the EGF-receptor: The transcriptional program underlying EGF-regulated cell proliferation, and an endocytic machinery underlying the response to cellular stress.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Jacob Berger A, Gigi E, Kupershmidt L, et al. (2021) IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy. Nature Cancer. 2: 1055-1070 |
| Ben-Hamo R, Jacob Berger A, Gavert N, et al. (2020) Predicting and affecting response to cancer therapy based on pathway-level biomarkers. Nature Communications. 11: 3296 |
| Zwang Y, Jonas O, Chen C, et al. (2017) Synergistic interactions with PI3K inhibition that induce apoptosis. Elife. 6 |
| Tarcic O, Granit RZ, Pateras IS, et al. (2017) RNF20 and histone H2B ubiquitylation exert opposing effects in Basal-Like versus luminal breast cancer. Cell Death and Differentiation |
| Baratta MG, Schinzel AC, Zwang Y, et al. (2015) An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 112: 232-7 |
| Zwang Y, Chen C, Hahn WC. (2015) Abstract C73: A drug-modifier whole-genome shRNA screen identifies novel synthetic lethal interactions with PI3K inhibition in breast cancer Molecular Cancer Therapeutics. 14 |
| Shao DD, Xue W, Krall EB, et al. (2014) KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 158: 171-84 |
| Lovejoy CA, Li W, Reisenweber S, et al. (2012) Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. Plos Genetics. 8: e1002772 |
| Zwang Y, Oren M, Yarden Y. (2012) Consistency test of the cell cycle: roles for p53 and EGR1. Cancer Research. 72: 1051-4 |
| Tarcic G, Avraham R, Pines G, et al. (2012) EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 26: 1582-92 |